Instagram Outage Disrupts Thousands of U.S. Users 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OSLO, Norway and VANCOUVER, British Columbia, May 23, 2017 -- Orkla Food Ingredients, a business area of Orkla ASA (OSE:ORK) has signed a licence agreement with Renaissance BioScience Corp. to exclusively produce and sell Renaissance acrylamide-reducing yeast to food manufacturers in the European Nordic and Baltic markets, starting in Q3 2017.
“Renaissance’s acrylamide-reducing yeast has shown promising results in baked goods trials, and Orkla is pleased to be working with Renaissance to make this valuable advance in food safety available to food manufacturers,” says Thore Svensson, Senior Vice President in Orkla Food Ingredients.
Dr. Cormac O’Cleirigh, Chief Business Development Officer at Renaissance BioScience comments: “Orkla is the market leader in the Nordics and Baltics, and we’re pleased to be working with a partner that sees the importance of reducing acrylamide in the food supply. This is a key region for the introduction of our acrylamide-reducing yeast, given that it is where the presence of acrylamide has the highest level of consumer awareness.”
Renaissance’s acrylamide-reducing yeast has shown promising results in large-scale industrial trials in baked goods and snack foods, as well as in lab scale tests in fries and coffee. This yeast was granted GRAS status by the U.S. FDA in 2016 — the same status as conventional baker’s and brewer’s yeasts. It is patent pending and was developed using classical non-GMO techniques. Renaissance is currently working with Orkla on final product development and commercial rollout.
About Orkla
Orkla is a leading supplier of branded consumer goods and concept solutions to the grocery, out-of-home and bakery markets in the Nordics, Baltics and selected markets in Central Europe and India. Orkla is listed on the Oslo Stock Exchange and its head office is in Oslo. In 2016, the Group had a turnover of approximately NOK 38 billion, and 18,000 employees at year end.
About Renaissance BioScience Corp.
Renaissance BioScience Corp., based in Vancouver, Canada, is a privately held applied life sciences company that develops novel, yeast-based, patent-protected technologies for the global food, beverage, nutrition, biofuel and pharmaceutical industries. The wholly owned commercial subsidiaries of Renaissance BioScience Corp. include Renaissance Yeast Inc., which commercializes H2S-preventing wine yeast; Renaissance Ingredients Inc., which commercializes acrylamide-reducing yeast; and Bright Brewers Yeast Inc., which commercializes beer yeast technologies. Detailed information about the Renaissance group of companies can be accessed at www.renaissancebioscience.com.
Orkla ASA
Oslo, 23 May 2017
Ref.: Orkla ASA Group Director, Corporate Communications and Corporate Affairs Håkon Mageli Tel.: + 47 928 45 828 Email: [email protected] Renaissance BioScience Corp. Steve Campbell Campbell & Company Strategies Inc. Communications and Public Relations Vancouver, BC CANADA Tel.: 01 604 888-5267 Email: [email protected]
